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Despite years of research, vaccines against HIV and HCV are not yet available, due largely
to effective viral immunoevasive mechanisms. A novel escape mechanism observed in
viruses that cause chronic infection is suppression of viral-specific effector CD4+ and
CD8+ T cells by stimulating regulatory T cells (Tregs) educated on host sequences during
tolerance induction. Viral class II MHC epitopes that share a T cell receptor (TCR)-face
with host epitopes may activate Tregs capable of suppressing protective responses. We
designed an immunoinformatic algorithm, JanusMatrix, to identify such epitopes and
discovered that among human-host viruses, chronic viruses appear more human-like than
viruses that cause acute infection. Furthermore, an HCV epitope that activates Tregs in
chronically infected patients, but not clearers, shares a TCR-face with numerous human
sequences. To boost weak CD4+ T cell responses associated with persistent infection,
vaccines for HIV and HCV must circumvent potential Treg activation that can handicap
efficacy. Epitope-driven approaches to vaccine design that involve careful consideration
of the T cell subsets primed during immunization will advance HIV and HCV vaccine
development.
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THE CHALLENGE
Despite modern advances in preventing disease by vaccination,
persistent viral infections continue to pose a major challenge to
vaccine development. The most prominent examples are HIV-1
and HCV infections, which remain two of the largest global public
health challenges today. Highly effective medications are now
available, but these are still inaccessible to the majority of at-risk
individuals mainly due to their cost, and limitations on access to
healthcare in the developing world countries where HIV and HCV
are most prevalent. Unfortunately, no vaccine candidate against
AIDS or hepatitis C is currently nearing market approval. Only
a handful of HIV vaccine efficacy trials have been completed,
and none have yet been completed for HCV (Honegger et al.,
2014). While a range of strategies to treat infection and prevent
transmission have been studied and implemented, it is widely
believed that an effective vaccine for these global health threats
is essential to stopping new infections worldwide.
Development of effective HIV and HCV vaccines is lagging
because traditional strategies for developing vaccines have failed
to overcome the ability of the viruses to evade the human
immune response. Many obstacles to vaccine development have
been uncovered: (i) extensive viral genetic diversity, enabling HIV
and HCV to evade humoral as well as cell-mediated immune
responses (von Hahn et al., 2007; Haaland et al., 2013), (ii) lack
of suitable animal models, (iii) establishment of latent reservoirs
following integration into the host genome soon after infection
(in the case of HIV; Perreau et al., 2013), and (iv) lack of clear
correlates of protective immunity. We recently hypothesized that
viruses that tend to cause chronic diseases mutate their T cell
epitopes toward greater homology with the human genome. The
existence of several highly homologous T cell epitopes, some
of which induce regulatory T cell (Treg) responses, has been
confirmed. We postulate that this is an important means by
which HIV and HCV evade effective T cell responses, and that
failure to account for such epitopes may have contributed to
the failure of certain vaccine approaches undertaken to date.
Methods for discovering HIV and HCV Treg-activating epitopes
and strategies for improving HIV and HCV vaccines are described
briefly here.
VIRUSES FIND NEWMEANS TO EVADE HUMAN IMMUNE
RESPONSES
No matter where one stands on the subject of the correlates of
immunity to HIV and HCV infection, it is generally acknowl-
edged that strong and broadly reactive HIV- and HCV-specific
CD4+ T cell responses are required for control of acute viral infec-
tions (Rosenberg et al., 1997; Gerlach et al., 1999). Early collapse
of the CD4+ T cell response impairs antibody production and
CD8+ T cell responses; thus, an effective vaccine needs to induce
long-lived CD4+ T cells capable of sustaining these essential
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components of immunity (Lichterfeld et al., 2004; Schulze Zur
Wiesch et al., 2012).
CD4+ T cells are activated by virus-specific epitopes presented
in the context of class II MHC by antigen presenting cells. Iden-
tification of class II MHC epitopes has been an active area of
research for characterization of antigen-specific HCV and HIV
CD4+ T cell responses in infection and vaccination and for
construction of epitope-driven vaccines (De Groot et al., 2004;
El-Awady et al., 2013; Karpenko et al., 2014; Mishra et al., 2014;
Takei et al., 2014). Long-standing criteria for characterizing class
II MHC epitopes include allele coverage in the human population
and virus coverage among circulating strains, measured by how
well an epitope represents a virus-induced response in the human
host. Our group has published and validated methods by which
this might be accomplished (De Groot et al., 2004; Koita et al.,
2006; Mishra et al., 2014).
A significant epitope property that is beginning to gain
wider attention is homology with host sequences. Viral epitopes
with substantial homology to self are, at best, inert because
of clonal deletion in the development of central tolerance; at
worst, they may activate Tregs that suppress protective inflam-
matory responses and thereby enable viral persistence (Rolland
et al., 2007; Frankild et al., 2008; Calis et al., 2012). It is well
established that HCV-induced Treg activation is associated with
extended chronic infections (Losikoff et al., 2012). Several studies
of chronic HCV subjects have shown increased frequencies of nat-
ural CD4+ Tregs that express high levels of CD25, produce IL-10
(Cabrera et al., 2004), TGF-β (Bolacchi et al., 2006), and FoxP3
(Li et al., 2007), and suppress IFN-γ production (Sugimoto et al.,
2003) and proliferation of HCV-specific CD8+ T cells (Boettler
et al., 2005; Rushbrook et al., 2005). In the case of HIV, the role of
Tregs in infection is currently being debated and requires further
investigation to identify Treg subsets that may be responsible
for suppressing non-specific T cell activation (beneficial) and of
HIV-specific effector T cell responses (detrimental; Chevalier and
Weiss, 2013).
We believe that vaccines for HIV and HCV must account for
potential Treg activation that can diminish efficacy, particularly
when a strong CD4+ T helper immune response is required.
Ideally, vaccines should be carefully designed to reduce or elim-
inate potential Treg-activating sequences. That is possible today
with the availability of immunoinformatic tools to predict class II
MHC epitopes that may stimulate Tregs.
For over 20 years and until very recently, T cell epitope-
mapping algorithms have focused on the MHC-facing side of
epitopes and ignored the T cell receptor (TCR) face; thus,
their usefulness was limited to identifying MHC ligands. While
MHC binding is necessary to stimulate a T cell response, it is
not sufficient. Hence, immunoinformatic-identified MHC lig-
ands have been screened experimentally for T cell activation to
validate predictions. Because Tregs are responsive to HIV and
HCV epitopes, T cell assays should be performed to ascertain
which T cell subsets are activated. Indeed, Treg-activating epi-
topes have been discovered using overlapping peptide arrays and
tetramers in HCV core, NS3, NS4, and NS5 antigens (Li et al.,
2007, 2009; Ebinuma et al., 2008; Langhans et al., 2010) and
HIV Gag (Angin et al., 2012). These approaches are extremely
cumbersome, however, when screens are conducted on a genomic
scale with the intent to broadly cover human MHC diversity.
ACCELERATING THE DISCOVERY OF VIRAL CAMOUFLAGE
SEQUENCES
An informatic tool that rapidly screens thousands of candidate
epitopes could address the problem of viral immune escape, but
also needs to consider the vast variability and degeneracy of TCRs,
making prediction extremely challenging. Fortunately, the prob-
lem can be significantly reduced by searching directly for virus-
encoded human homologs that potentially stimulate natural and
inducible Tregs, even if some Treg-activating epitopes are not
necessarily human homologs. Specifically, pathogen sequences
that bind MHC and share the same TCR-face with human MHC
ligands may stimulate pre-existing Tregs that emerged from devel-
opment of central and peripheral tolerance. Shared sequence
patterns on the TCR-face are easily searchable.
To better define and rapidly assess viral camouflage epi-
topes, i.e., those epitopes homologous to human, we developed
the JanusMatrix algorithm, which leverages our existing algo-
rithm (EpiMatrix) to define MHC-binding peptide epitopes while
searching for cross-conservation at the TCR-face. JanusMatrix can
be applied to any viral or bacterial target protein to compare
its TCR-faces to others in any genomes of interest. JanusMatrix
analyzes the two faces of peptide sequences of pathogen origin
for T cell activation potential (Moise et al., 2013). MHC-facing
residues are analyzed for MHC binding potential using the Epi-
Matrix epitope-mapping algorithm (De Groot et al., 1997). We
have examined TCR-facing residues for conservation against a
variety of sequence databases, including the complete human
proteome, the human microbiome, and human pathogens (Moise
et al., 2013). For example, we screened a wide range of human-
host viruses for TCR-face similarity to self and discovered that
chronic viruses generally appear more human-like than viruses
that cause acute infection (He et al., 2014), and that H7N9
influenza may evade immune response in a similar way (De Groot
et al., 2013, 2014).
Using JanusMatrix, we discovered a promiscuous class II epi-
tope located within non-structural HCV protein p7 that exhibits
homology with hundreds of human sequences (Figure 1). The
epitope induces an increase in CD4+CD25+FoxP3+ Treg num-
ber and function in peripheral blood leukocyte cultures derived
from an HLA-diverse cohort of HCV-infected patients, but not
in cultures derived from patients who spontaneously cleared
HCV or from non-infected individuals (Losikoff et al., 2014).
A human analog of the HCV epitope stimulates Tregs in both
HCV-infected and non-infected people, suggesting that toler-
ance to HCV is promoted by activating Tregs that recognize a
common TCR-face. It is well known that HCV and HIV CD8+
and CD4+ T cell epitopes mutate over the course of infection,
decreasing MHC binding as a mechanism of viral escape (Har-
court et al., 1998; Norris et al., 2006; Petrovic et al., 2012).
The p7 HCV epitope exhibits a novel escape mechanism, evolv-
ing a TCR-face similar to that found in autologous T cell epi-
topes, thus stimulating Treg responses and suppressing immune
clearance.
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FIGURE 1 | Predicted Treg-activating HIV and HCV sequences
possess TCR faces shared by numerous human proteins. Epitope
networks are shown, illustrating the abundance of TCR faces one HCV
and one HIV peptide share with the human genome as determined by
JanusMatrix analysis. The HIV and HCV source peptides are
represented by green diamonds, their constituent 9-mer epitopes by
gray squares, their cross-conserved partners in the human genome by
blue triangles, and the source human proteins by light purple circles. In
the HIV peptide (right) a single cross-conserved epitope can be found
in 32 different HLA class I alleles; several additional 9-mer epitopes are
cross-conserved with 12 other HLA sequences (source protein orange
highlight).
At first glimpse, JanusMatrix analysis indicates that HIV also
exhibits curious patterns of potential T cell cross-reactivity. While
searching HIV envelope sequences for TCR-face conservation in
the human genome, we recently uncovered a high frequency of
human MHC (HLA) molecule sequences that share a TCR-face
with a highly conserved epitope located in the HIV envelope
protein (orange circles, Figure 1). Because HLA is highly variable
in the human population, conservation of this sequence across
HLA subtypes is noteworthy. The phenotype of T cells responding
to this epitope has not yet been evaluated in our laboratory but
an Immune Epitope Database search identified a closely related
epitope capable of stimulating CD4+ T cell recognition and
proliferation (Atassi and Atassi, 1992). If these CD4+ T cells are
T-effector in nature, their activation could restrict HIV expansion
(Sanjuán et al., 2013). We believe that it is more likely, however,
that T cells that recognize this epitope possess a Treg phenotype,
which may promote HIV expansion and/or persistence instead.
These HIV and HCV epitope examples are consistent with
our previously published observation that “hit-and-stay” viruses
escape protective immune responses by stimulating cross-reactive
Tregs (He et al., 2014). This suggests that Treg-activating HCV
and HIV sequences may affect HCV and HIV vaccine efficacy. We
find similar patterns of cross reactivity in EBV, CMV, and HSV, all
viruses that establish chronic infection and for which no vaccine
exists.
ADDRESSING VIRAL CAMOUFLAGE IN VACCINE DESIGN
Homology with the human genome represents a novel means
by which viruses that seek to establish chronic infections escape
human immunity and ensure their survival. Better classification
of viral epitopes as either effector- or Treg-activating will improve
the design of HIV and HCV vaccines. Knowledge of which epi-
topes to include or exclude makes it possible to generate virus-
specific T cell responses that are essential for protection and
that sidestep suppression. One potential solution to the challenge
of HCV and HIV vaccine design is to develop epitope-driven
subunit vaccines, either as whole antigen protein vaccines, using
a structure-based approach, or alternatively, as platform-neutral
epitope-based vaccines that do not contain Treg-activating epi-
topes. Such vaccines would have major advantages over conven-
tional, but as yet unsuccessful approaches because they would
simultaneously account for viral and human diversity for the
purpose of broad reactivity and promote protective virus-specific
T cell responses.
Importantly, the impact of Treg-activating epitopes may have
different inhibitory effects depending on the level of viral replica-
tion and immune activation in acute or chronic HIV infection.
Thus, Treg epitopes to exclude may differ for prophylactic and
therapeutic HIV vaccines. With respect to HCV, we believe the
maximum effectiveness of an HCV vaccine used either prophylac-
tically or therapeutically would be achieved by always excluding
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Treg-activating epitopes because (i) unlike HIV, which infects
and replicates in Tregs, HCV is primarily hepatotropic and (ii)
a better understanding of Treg function in chronic HCV infection
could lead to treatments that are capable of balancing the com-
peting needs for sustained effector T cell-mediated immunity and
limited tissue damage moderated by Tregs (Self et al., 2013).
Finally, we are exploring means to fine-tune the epitope con-
tent of HIV and HCV vaccines to induce nuanced T cell responses
associated with protection. We believe that careful design is
needed to improve efficacy. Cross-reactivity at the individual
level owing to HLA and HIV or HCV sequence variation may
necessitate the development of personalized vaccines that contain
T effector, but not Treg epitopes. While personalized vaccines
may seem futuristic, tools are available to design such vaccines.
As this technology becomes ever more accessible, there will be
an even greater incentive to define the means of personalizing
vaccines.
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